OverviewSuggest Edit

The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding of the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein homeostasis, the stabilization and degradation of cellular proteins. This process is vital to the healthy life of a cell and provides opportunities to discover new drugs in multiple disease areas. Nurix’s Protein Regulation Platform enables the discovery of selective inhibitors or activators of the UPS, enabling the development of new class of drugs. In September 2015, Nurix entered into an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology. Nurix was founded by internationally-recognized experts in the ubiquitin proteasome field and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California.
TypePrivate
Founded2009
HQSan Francisco, CA, US
Websitenurixtx.com
Employee Ratings4.1
Overall CultureA+

Latest Updates

Employees (est.) (Dec 2021)219(+6%)
Job Openings18
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Nurix

Arthur T. Sands

Arthur T. Sands

President, Chief Executive Officer, and Director
David Lacey

David Lacey

Chairman
Jeff Tong

Jeff Tong

Director
Hans van Houte

Hans van Houte

Chief Financial Officer
Stefani A. Wolff

Stefani A. Wolff

Chief Operating Officer and Executive Vice President, Product Development
Lori A. Kunkel

Lori A. Kunkel

Director
Show more

Nurix Office Locations

Nurix has an office in San Francisco
San Francisco, CA, US (HQ)
1700 Owens St #205, San Francisco
Show all (1)

Nurix Financials and Metrics

Summary Metrics

Founding Date

2009

Nurix total Funding

$165.2 m

Nurix latest funding size

$120 m

Time since last funding

2 years ago

Nurix investors

Nurix's latest funding round in March 2020 was reported to be $120 m. In total, Nurix has raised $165.2 m
Show all financial metrics

Nurix Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Nurix Online and Social Media Presence

Embed Graph

Nurix Company Culture

  • Overall Culture

    A+

    94/100

  • CEO Rating

    A-

    80/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Nurix News and Updates

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

Nurix leads protein modulation field with four active clinical stage programs

Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix will present an overview of corporat…

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL
Show more

Nurix Blogs

Christopher B. Phelps, Ph.D.

Chris Phelps has served as Vice President and Head of Early Discovery at Nurix since January 2021. Chris has more than 10 years of experience in small molecule discovery, with a focus on DNA encoded library technology. Prior to joining Nurix, he served in multiple roles at GSK, most recently as Dire…

Scientist I/Scientist II, Process Chemistry, Chemical Development

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases t…

Scientist I/Scientist II, Analytical Development, CMC

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases t…

Software Engineer/Sr. Software Engineer, Research Informatics

Nurix is looking for a highly motivated informatics software engineer to design, develop, and deliver innovative software applications and digital solutions for scientific research and drug discovery.  This is a new role that provides the opportunity to establish and shape Nurix software development…

Structural Biology Scientist

We are seeking an experienced and enthusiastic Structural Biologist with expertise in crystallography to join the Drug Discovery team at Nurix. Nurix is devoted to unlocking the therapeutic potential of the ubiquitin proteasome system (UPS) in the areas of oncology and immuno-oncology, by utilizing …

Biophysics Scientist I

We are seeking a highly skilled and motivated Scientist with expertise in Biophysics to join Nurix’s Discovery team. You will provide scientific leadership in Nurix’s biophysics efforts to help support our hit identification, hit-to-lead and structural biology efforts. You will play a key role in co…
Show more

Nurix Frequently Asked Questions

  • When was Nurix founded?

    Nurix was founded in 2009.

  • Who are Nurix key executives?

    Nurix's key executives are Arthur T. Sands, David Lacey and Jeff Tong.

  • How many employees does Nurix have?

    Nurix has 219 employees.

  • Who are Nurix competitors?

    Competitors of Nurix include Foghorn Therapeutics, IDEXX and Particular Sciences.

  • Where is Nurix headquarters?

    Nurix headquarters is located at 1700 Owens St #205, San Francisco, San Francisco.

  • Where are Nurix offices?

    Nurix has an office in San Francisco.

  • How many offices does Nurix have?

    Nurix has 1 office.